The American Journal of Managed Care

Epcoritamab Plus Chemoimmunotherapy Yields 87% Response Rate in R/R DLBCL; 65% Proceed to Transplant

Epcoritamab plus chemoimmunotherapy achieved an 87% overall response rate in relapsed/refractory DLBCL patients, with 65% achieving complete response. The regimen offers a potential bridge to ASCT or ...
collider

The Best R-Rated Movies on Disney+ With Hulu Right Now (July 2024)

Tauri Jay Miller is a Voice Over Actor, Writer, and Podcaster who LOVES Tabletop RPGs. Originally from the San Francisco Bay Area, he is a graduate of the Radio and Television program at San Francisco ...
ascopubs.org

Phase 3 trial of odronextamab plus lenalidomide versus rituximab plus lenalidomide in relapsed/refractory (R/R) follicular lymphoma (FL) and marginal zone lymphoma (MZL ...

Phase 3 trial evaluating the efficacy and safety of odronextamab versus standard-of-care (SOC) therapy in relapsed/refractory (R/R) aggressive B-cell non-Hodgkin lymphoma (B-NHL; OLYMPIA-4). This is ...
ascopubs.org

Pembrolizumab Plus Carboplatin and Paclitaxel as First-Line Therapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-B10): A Single-Arm Phase IV Trial

Neoadjuvant Chemotherapy With Oxaliplatin and Fluoropyrimidine Versus Upfront Surgery for Locally Advanced Colon Cancer: The Randomized, Phase III OPTICAL Trial Eligible adults had previously ...